Get the Stockscreener App
1.70
5.56%
-0.10
After Hours:
1.70
Aprea Therapeutics Inc Stock (APRE) Forecast
The Aprea Therapeutics Inc (APRE) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $226.02, representing a +13,195% increase from the current price of $1.70. The highest analyst price target is $285.22, and the lowest is $166.82.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month APRE Price Target
Average 222.52
(+12,989% Upside)
Is Aprea Therapeutics Inc (APRE) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 23.09 | Buy |
| STOCH(9,6) | 3.7444 | Buy |
| STOCHRSI(14) | 44.75 | Neutral |
| MACD(12,26) | -0.2595 | Sell |
| ADX(14) | 17.63 | Neutral |
| William %R | -96.94 | Buy |
| CCI(14) | -143.90 | Sell |
Buy: 3
Sell: 2
Neutral: 2
Summary: Buy
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
2.031
Sell
|
1.9925
Sell
|
| MA20 |
2.2032
Sell
|
2.1883
Sell
|
| MA50 |
2.8258
Sell
|
2.6238
Sell
|
| MA100 |
3.1108
Sell
|
2.983
Sell
|
| MA200 |
3.3375
Sell
|
3.5205
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, APRE could be considered a Strong Sell, with 17 technical analysis indicators signaling 3 Buy signals, 12 signaling Sell signals and 2 Neutral signals. This might not be a good time to consider opening new positions on APRE, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 23.09 indicates that APRE is oversold. This indicates that APRE price has experienced a significant decline over a specified lookback period, potentially leading to a rebound.
- STOCH (Stochastic Oscillator): The STOCH value of 3.7444 indicates that APRE is oversold. This indicates that APRE price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 44.75 indicates that APRE is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 17.63 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -143.9 indicates that APRE is oversold. This means that the price has moved significantly lower than its average, indicating a potential buying opportunity.
Long-term APRE price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Aprea Therapeutics Inc financial reports and earnings history, Aprea Therapeutics Inc (APRE) stock could reach $138.20 by 2030, $915.94 by 2040 and $92.61 by 2050. See the projected annual prices until 2050 of the Aprea Therapeutics Inc stock below:
- Aprea Therapeutics Inc (APRE) is expected to reach an average price of $343.81 in 2035, with a high prediction of $270.73 and a low estimate of $259.10. This indicates an $20,124% rise from the last recorded price of $1.70.
- Aprea Therapeutics Inc (APRE) stock is projected to chart a bullish course in 2040, with an average price target of $928.64, representing an $54,526% surge from its current level. The forecast ranges from a conservative $967.84 to a sky-high $915.94.
- Our analysts predict Aprea Therapeutics Inc (APRE) to jump 87,752% by 2045, soaring from $21.11 to an average price of $1,493.48, potentially reaching $1,460.75. While $21.11 is the low estimate, the potential upside is significant.
- Aprea Therapeutics Inc (APRE) stock is expected to climb by 2050, reaching an average of $74.73, a $4,296% jump from its current level. However, a wide range of estimates exists, with high and low targets of $92.61 and $75.06, respectively, highlighting the market's uncertainty.
Aprea Therapeutics Inc Stock (APRE) Year by Year Forecast
Aprea Therapeutics Inc Stock (APRE) Price Forecast for 2025
Aprea Therapeutics Inc Stock (APRE) is expected to reach an average price of $304.52 in 2025, with a high prediction of $503.86 and a low estimate of $105.18. This indicates an +17,813% rise from the last recorded price of $1.70.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $239.62 | $166.82 | $285.22 | +13,995% |
| June, 2025 | $206.11 | $126.57 | $329.79 | +12,024% |
| July, 2025 | $119.78 | $105.18 | $304.69 | +6,946% |
| August, 2025 | $217.48 | $108.06 | $277.28 | +12,693% |
| September, 2025 | $224.58 | $190.25 | $339.86 | +13,110% |
| October, 2025 | $159.95 | $167.95 | $169.48 | +9,309% |
| November, 2025 | $144.26 | $133.61 | $125.86 | +8,386% |
| December, 2025 | $155.99 | $150.14 | $154.99 | +9,076% |
Aprea Therapeutics Inc Stock (APRE) Price Forecast for 2026
The predicted value for Aprea Therapeutics Inc (APRE) in 2026 is set at an average of $136.54. Estimates vary from a peak of $161.17 to a trough of $111.90, indicating an +7,931% surge from the present price of $1.70.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $163.29 | $156.41 | $158.49 | +9,505% |
| February, 2026 | $162.20 | $160.92 | $161.17 | +9,441% |
| March, 2026 | $145.10 | $146.10 | $158.62 | +8,435% |
| April, 2026 | $133.83 | $135.20 | $138.73 | +7,772% |
| May, 2026 | $156.14 | $149.26 | $142.54 | +9,084% |
| June, 2026 | $129.84 | $134.64 | $150.96 | +7,538% |
| July, 2026 | $117.27 | $121.57 | $127.27 | +6,798% |
| August, 2026 | $112.27 | $115.62 | $105.85 | +6,504% |
| September, 2026 | $123.60 | $111.90 | $120.40 | +7,171% |
| October, 2026 | $131.51 | $130.43 | $130.11 | +7,636% |
| November, 2026 | $147.41 | $141.78 | $141.41 | +8,571% |
| December, 2026 | $151.14 | $150.09 | $147.86 | +8,791% |
Aprea Therapeutics Inc Stock (APRE) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Aprea Therapeutics Inc (APRE) is $129.19, with a high forecast of $149.37 and a low forecast of $109.02. This indicates an +7,500% increase from the last price of $1.70.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $146.45 | $150.05 | $149.37 | +8,514% |
| February, 2027 | $138.55 | $139.15 | $139.70 | +8,050% |
| March, 2027 | $142.05 | $139.58 | $138.23 | +8,256% |
| April, 2027 | $146.43 | $147.17 | $146.72 | +8,514% |
| May, 2027 | $141.68 | $142.09 | $144.31 | +8,234% |
| June, 2027 | $128.22 | $132.02 | $138.94 | +7,442% |
| July, 2027 | $128.30 | $128.29 | $128.07 | +7,447% |
| August, 2027 | $125.33 | $125.98 | $125.20 | +7,272% |
| September, 2027 | $117.76 | $121.06 | $120.08 | +6,827% |
| October, 2027 | $114.32 | $114.46 | $116.38 | +6,625% |
| November, 2027 | $113.67 | $114.77 | $115.54 | +6,586% |
| December, 2027 | $108.48 | $109.02 | $110.95 | +6,281% |
Aprea Therapeutics Inc Stock (APRE) Price Forecast for 2028
In 2028, Aprea Therapeutics Inc (APRE) is projected to reach an average price of $71.49, with a high projection of $103.08 and a low estimate of $39.90. This indicates an +4,105% rise from the last price of $1.70.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $100.12 | $100.56 | $103.08 | +5,790% |
| February, 2028 | $97.18 | $96.28 | $98.03 | +5,617% |
| March, 2028 | $92.06 | $92.30 | $96.12 | +5,316% |
| April, 2028 | $87.64 | $87.70 | $90.62 | +5,055% |
| May, 2028 | $81.03 | $81.22 | $85.98 | +4,667% |
| June, 2028 | $75.79 | $76.08 | $79.63 | +4,358% |
| July, 2028 | $70.99 | $71.10 | $74.37 | +4,076% |
| August, 2028 | $63.01 | $64.06 | $69.18 | +3,606% |
| September, 2028 | $57.81 | $58.05 | $61.32 | +3,301% |
| October, 2028 | $51.86 | $52.00 | $56.15 | +2,951% |
| November, 2028 | $45.61 | $45.63 | $50.22 | +2,583% |
| December, 2028 | $39.88 | $39.90 | $44.12 | +2,246% |
Aprea Therapeutics Inc Stock (APRE) Price Forecast for 2029
The 2029 price forecast for Aprea Therapeutics Inc Stock (APRE) is $174.91 on average, with a high prediction of $348.37 and a low estimate of $1.4517. This represents an +10,189% increase from the previous price of $1.70.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $33.04 | $33.21 | $38.32 | +1,843% |
| February, 2029 | $25.89 | $26.25 | $30.52 | +1,423% |
| March, 2029 | $19.79 | $20.78 | $23.89 | +1,064% |
| April, 2029 | $12.29 | $12.57 | $17.79 | +623.02% |
| May, 2029 | $7.1216 | $7.4216 | $10.52 | +318.92% |
| June, 2029 | $2.8257 | $3.0256 | $5.6476 | +66.22% |
| July, 2029 | $318.80 | $1.4517 | $332.30 | +18,653% |
| August, 2029 | $136.06 | $254.16 | $231.31 | +7,904% |
| September, 2029 | $15.73 | $198.67 | $188.37 | +825.14% |
| October, 2029 | $122.67 | $4.4232 | $348.37 | +7,116% |
| November, 2029 | $4.8589 | $16.54 | $164.42 | +185.82% |
| December, 2029 | $40.45 | $26.15 | $74.05 | +2,279% |
Aprea Therapeutics Inc Stock (APRE) Price Forecast for 2030
Aprea Therapeutics Inc Stock (APRE) is expected to reach an average price of $231.22 in 2030, with a high forecast of $443.95 and a low forecast of $18.49. This signifies an +13,501% surge from the last price of $1.70.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $52.81 | $44.16 | $138.20 | +3,006% |
| February, 2030 | $25.82 | $18.49 | $48.05 | +1,419% |
| March, 2030 | $70.63 | $47.17 | $122.53 | +4,054% |
| April, 2030 | $118.37 | $71.41 | $119.77 | +6,863% |
| May, 2030 | $52.49 | $42.04 | $185.41 | +2,988% |
| June, 2030 | $62.50 | $66.65 | $53.80 | +3,577% |
| July, 2030 | $60.96 | $58.15 | $47.14 | +3,486% |
| August, 2030 | $88.97 | $52.62 | $107.12 | +5,134% |
| September, 2030 | $142.98 | $82.82 | $37.38 | +8,311% |
| October, 2030 | $65.24 | $72.24 | $106.83 | +3,738% |
| November, 2030 | $52.65 | $40.54 | $59.88 | +2,997% |
| December, 2030 | $429.26 | $440.66 | $443.95 | +25,150% |
10.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):